Search results | hepatitis

Reports

Hepatitis Partnering

The Hepatitis Partnering provides understanding and access to the hepatitis partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Bio news: Achillion deal looming as hepatitis drugs fail: Real M&A

Achillion Pharmaceuticals Inc. , the developer of hepatitis C treatments, makes bio news with  renewed interest in the hepatitis drug market after setbacks by rival drugmakers.

J&J Open to Expanding Hepatitis C Cooperation With Vertex

Johnson & Johnson (JNJ)’s Janssen unit said it may explore widening cooperation on hepatitis C withVertex Pharmaceuticals that may develop in tandem with a separate partnership with Medivir on the disease

Merck Hepatitis C Drug May ‘Anchor’ Future Worldwide Regimen

Merck & Co. will make whatever deals are necessary to ensure the company leads the race for future hepatitis C combination therapies, said Roger Pomerantz, the drugmaker’s worldwide head of licensing and acquisitions

Who’s next in the hepatitis C acquisition trail?

The recent acquisition of Pharmasset for a record breaking drug maker acquisition by Gilead has got markets asking who will be next

M&A rumors for buyout of Achillion Pharmaceuticals by big pharma

UBS analyst Andrew Peters suggested that a recent takeover big in the biotech space of California-based InterMune, Inc.  by Roche was the harbinger of more M&A rumors to come.

SciClone Pharmaceuticals: Your marketing partner for China

Sciclone Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing products to treat oncology, infectious diseases and urology.

Life Science M&A Deal Trends in Q2, 2014

By Steve Poile                                     With 110 deals announced, the second quarter continued on from the strong start for life science M&A during 2014.

Cancer vaccine

A cancer vaccine is a vaccine that treats existing cancer or prevents the development…

Emergent biosolutions: Bio-defensively protecting and enhancing life

Emergent Biosolutions is a specialty pharmaceutical company developing products to protect and enhance human and childrens lives by working with healthcare providers and governments.

Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a top pharmaceutical company based in New York, NY, USA.

Events

Sorry, your search returned no results.


Deals

Vertex pharma partners with Johnson & Johnson and Achillion for hepatitis C

Vertex Pharmaceuticals has received interest from other companies to be pharma partners on tests of one of its experimental medicines for the liver disease

Bio news: Achillion deal looming as hepatitis drugs fail: Real M&A

Achillion Pharmaceuticals Inc. , the developer of hepatitis C treatments, makes bio news with  renewed interest in the hepatitis drug market after setbacks by rival drugmakers.

Bristol-Myers Squibb Foundation announces grants focussed on prevention, diagnosis and care of Hepatitis B and Hepatitis C in Asia

The Bristol-Myers Squibb Foundation has awarded three new grants to improve prevention, diagnosis and care of hepatitis B (HBV) and hepatitis C (HCV) in China and India as part of its Delivering Hope: Awareness, Prevention and Care umbrella program which is committed to reducing hepatitis-related health disparities in Asia.

BMS and Tibotec to develop hepatitis C combination therapy

Clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate the utility of daclatasvir (BMS-790052), Bristol-Myers Squibb’s investigational NS5A replication complex inhibitor, in combination with Tibotec Pharmaceuticals’ investigational NS3 protease inhibitor, TMC435

Gilead and GlaxoSmithKline in agreement to commercialize Viread for chronic hepatitis B in key Asian countries

Licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia.

Boehringer Ingelheim acquires Pharmaxis’ anti-inflammatory candidate

Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis’ investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights.

Janssen and Ichor Medical enter hep B vaccine delivery alliance

Ichor Medical Systems has entered into a product development collaboration and worldwide license agreement with Janssen Pharmaceuticals

Merck and NGM collaborate on biologic therapies

NGM Biopharmaceuticals and Merck have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas

Mylan and Gilead partner for Sovaldi and Harvoni in India

Mylan has been appointed as the exclusive distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni

Gilead and Mylan expand Sovaldi pact

Mylan Laboratories is expanding its hepatitis C licensing agreement with Gilead Sciences to include the non-exclusive rights to manufacture and distribute the investigational NS5A inhibitor GS-5816